PKHB1 Tumor Cell Lysate Induces Antitumor Immune System Stimulation and Tumor Regression in Syngeneic Mice with Tumoral T Lymphoblasts

Figure 5

PKHB1-TCL treatment in L5178Y-R-tumor-bearing mice induce tumor regression. (a) Schema of PKHB1-TCL (5 × 10⁶ CC₁₀₀ PKHB1-treated L5178Y-R cells) treatment started when tumor reached 100 mm³, and then PKHB1-TCL was administrated every 3 days for two weeks (for a total of four injections). (b) Graph indicates tumor volume (±SD) of untreated mice (control; n = 7) or PKHB1-TCL-treated mice (PKHB1-TCL; n = 9). (c) Kaplan-Meier survival curve of untreated mice (control; n = 7) or PKHB1-TCL-treated mice (PKHB1-TCL; n = 9) over time.

(a)

(b)

(c)